By Fineline Cube 
Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment from Intas Pharmaceuticals Ltd. under a licensing and commercialization agreement signed on February 10 , 2025.
Deal Highlights
- Exclusivity – Intas, via its U.S. subsidiary Accord BioPharma Inc., holds the exclusive rights to commercialize BAT2506 (golimumab) in the United States.
- Roles – Bio‑Thera will continue to conduct R&D, manufacture, and supply the product; Intas will manage all U.S. commercial activities.
- Financial Scope – The partnership could yield up to $164.5 million in total upfront and milestone payments, comprising a $21 million upfront fee and up to $143.5 million in milestones. Bio‑Thera also stands to earn a double‑digit percentage of net U.S. sales.
Regulatory Milestones
BAT2506 has already received marketing‑application approvals from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), positioning the drug for a global launch.
Strategic Implications
- For Bio‑Thera – The milestone confirms the commercial viability of its golimumab platform and underscores the company’s ability to secure high‑value partnerships.
- For Intas – The deal expands its portfolio in the competitive U.S. biologics market, leveraging Intas’s distribution network and Accord BioPharma’s commercialization expertise.
- Market Outlook – With an established regulatory footing and a robust financial framework, BAT2506 is poised to capture significant market share in the rheumatology and inflammatory‑disease segments.-Fineline Info & Tech